HOME >> BIOLOGY >> NEWS
Results from open-label Raptiva study suggest continued benefit with long-term treatment

Genentech, Inc. and XOMA Ltd. today announced preliminary results from an open-label, multicenter trial evaluating the long-term safety and tolerability of continuous RaptivaTM (efalizumab) treatment in patients with moderate-to-severe psoriasis.

"The findings from this important open-label study on the long-term safety and efficacy of Raptiva are very encouraging and further support Raptiva's potential to address the unmet medical need of patients with moderate-to-severe psoriasis," said Hal Barron M.D., FACC, Genentech's vice president, Medical Affairs.

Alice Gottlieb, M.D., director of the Clinical Research Center at the Robert Wood Johnson Medical School at the University of Medicine and Dentistry of New Jersey presented data for patients receiving continuous Raptiva treatment for one year following an initial three months of treatment. The data were presented on Saturday, March 22 at the 61st annual American Academy of Dermatology meeting being held in San Francisco.

Response Rates with Continued Raptiva Treatment

A total of 339 patients were enrolled in this continuing open-label, multicenter study. 41 percent of patients (140/339) achieved 75 percent or greater improvement in Psoriasis Area and Severity Index (PASI) scores (PASI 75) and 82 percent (278/339) achieved PASI 50 or greater improvement after 12 weeks of 2 mg/kg/week Raptiva therapy. Patients who achieved a PASI 50 score or OLS (Overall Lesion Severity scale) of clear, minimal or mild at week 12 were eligible to enter the continuous treatment period. Of the original 339 patients, 290 patients who met the entry criteria for the maintenance period entered the continuous treatment phase of the study. For each successive three-month period of treatment, dropouts during that cohort period were counted as non-responders for that cohort, but were excluded from the subsequent cohorts.

Starting from week 13, the wee
'"/>

Contact: Emmy Tsui
emmy.tsui@ketchum.com
646-935-4019
Ketchum
24-Mar-2003


Page: 1 2 3 4 5

Related biology news :

1. Results of pivotal study for GlaxoSmithKlines Valtrex published in New England Journal of Medicine
2. NASA Materials Conference Features Science Results, Experts on Technologies for Exploration
3. Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research
4. Encouraging Results In Preclinical Studies Of Parkinsons Disease Gene Therapy
5. Quicker Implementation Of Research Results
6. Results Of Poisoning Visible In Urine
7. Phase III Results Suggest Potent Antiviral Activity For Vertex And Glaxo Wellcomes Second-Generation HIV Protease Inhibitor Agenerase TM
8. New Gene Therapy Technique Results In Efficient Gene Delivery
9. False Security: You Cant Always Believe The Results Of A Genetic Test
10. Cell Pathways Reports Extension Study Results Showing Ability Of FGN-1 To Prevent Formation Of Precancerous Colon Polyps
11. Results Of Hog-Stress Study May Lead To Better Management Methods

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/3/2020)... ... September 03, 2020 , ... Brilliant , the leading ... and its products are now available for purchase in the U.S., Canada, and Puerto ... AV, and low-voltage products. In addition to being available for purchase through ADI’s ...
(Date:9/3/2020)... , ... September 03, 2020 , ... ... data, today announced that an extensive third-party assessment of the company’s security practices ... when measured against federal security regulations. The comprehensive evaluation reviewed Litmus’ processes and ...
(Date:8/26/2020)... DIEGO and SHANGHAI (PRWEB) , ... August 24, ... ... pursuing novel approaches for the treatment of chronic inflammatory and fibrotic diseases, today ... Officer and Vice President of Drug Discovery. , Dr. Canan previously served as ...
Breaking Biology News(10 mins):
(Date:9/3/2020)... Mo. (PRWEB) , ... September 03, 2020 , ... ... 2020, will feature 15+ expert speakers to present updates on their latest research ... highlight innovative technologies and their impact in clinical diagnostics and therapeutic development, as ...
(Date:9/1/2020)... , ... September 01, 2020 , ... ... sciences, biotechnology, and diagnostics companies, has announced the placement of Julianne Averill ... be responsible for leading all financial operations and implementing key business strategies to ...
(Date:8/31/2020)... , ... August 29, 2020 , ... ... Animal Nutrition manufacturing capability in Wuxi, China. The new plant operation will provide ... standards and advanced technology. , “This facility will improve the flexibility of ...
(Date:8/15/2020)... ... August 13, 2020 , ... True Terpenes , the leading ... Scientific Advisory Board (SAB) to research the medical potential of terpenes and the potential ... combined with terpenes. The board is focused on expanding the recently launched line of ...
Breaking Biology Technology:
Cached News: